Open science delivers a wealth of AD/ADRD research data to a portal near you | National Institute on Aging

“The COVID-19 pandemic mobilized the global research and development community to embrace open science practices to accelerate the development of effective treatments. As described in this recent commentary by law professor Richard Gold, the COVID-19 crisis is an opportunity to move toward an open science drug discovery model to combat existing and future pandemics.

During the NIH Alzheimer’s Disease Research Summits in 2012, 2015, and 2018, we heard similar calls for open science from a large multi-stakeholder community in Alzheimer’s disease and related dementias (AD/ADRD) research. The collective input was the impetus for NIA to develop an array of new translational infrastructure programs, including AMP-AD and affiliated target discovery consortia (M2OVE-AD, Resilience-AD, and Psych-AD), and the MODEL-AD and TREAT-AD centers — all of which operate under open science principles — to rapidly deliver data, knowledge, and research tools necessary to overcome key barriers to developing effective therapies….”